KCT0006190尚未招募未知
Randomized phase II study of talazoparib versus talazoparib plus atezolizumab after palbociclib combination endocrine therapy for patients with premenopausal HR+/HER2- metastatic breast cancer harboring HRD scar
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20?(Year) 至 0No Limit（—）
- 性别
- Female
入选标准
- •1) Histologically confirmed metastatic breast cancer with or without measurable disease
- •2) Patients who have stage IV breast cancer at diagnosis (de novo) or have progressed on distant metastatic sites after curative surgery
- •3) Confirmed germline pathogenic BRCA1 and/or 2 mutation or 35 HRD-related gene alterations
- •4) age > 19 years
- •5) ECOG performance status 0 – 2
- •6) Patient has HER2-negative breast cancer with IHC and/or FISH (or SISH, CISH)
- •7) Patient has ER positive and/or PR positive breast cancer by local laboratory testing
- •8) Patient is premenopausal. Premenopausal status is defined as either:
- •A Patient had last menstrual period within the last 12 months
- •B. If on tamoxifen within the past 3 months, with a plasma estradiol =10 pg/mL and FSH =40 IU/l or in the premenopausal range, according to local laboratory definition
- •C. in case of chemotherapy induced amenorrhea, with a plasma estradiol =10 pg/mL) and/or FSH =40IU/l or in the premenopausal range according to local laboratory definition.
- •9) Patient with treatment history as bellows:
- •A In patients with de novo metastatic breast cancer(who had stage IV disease at first diagnosis of breast cancer),
- •B. In patients with recurrent metastatic breast cancer, recurrence during or after completion or discontinuation of adjuvant endocrine therapy (regardless of the treatment free interval) are eligible.
- •C. One line of prior cytotoxic chemotherapy(except platinum based chemotherapy) in metastatic breast cancer is permitted.
- •10) No possibility of pregnancy and urine or serum beta-HCG negative
- •11) Adequate bone marrow function (= ANC 1,500/ul, = platelet 100,000/ul, = Hemoglobin 9.0 g/dl)
- •12) Adequate renal function (= serum creatinine 1.5 mg/dl or CCr = 650 ml/min)
- •13) Adequate liver function (= serum bilirubin 2.0 mg/dl, = AST/ALT x 3 upper normal limit)
- •14) Patients who were already established on bisphosphonate therapy or denosumab may continue.
- •15) Patients agreed to use effective contraception or not of childbearing potential
- •16) Written informed consent
- •17) Patients agreed to offer tumor tissue and blood for biomarker analysis
排除标准
- •1) Postmenopausal women
- •2) Serious uncontrolled intercurrent infections within 4 weeks prior to Cycle 1 Day 1 of 1st Treatment
- •3) Serious intercurrent medical or psychiatric illness, including active cardiac disease
- •4) Pregnancy or breast feeding within 5 months after the last dose of atezolizumab
- •5) Second primary malignancy(except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or resected thyroid papillary carcinoma or other malignancy treated at least 5 years previously with no evidence of recurrence)
- •6) Patients has received previous endocrine treatments in the metastatic setting
- •7) Patients has received previous aromatase inhibitor
- •8) Patients has received previous treatment with CDK 4/6 inhibitors, PARP1 inhibitors, and immune check point inhibitors
- •9) Symptomatic visceral metastases, which means lymphangitic lung metastasis and/or symptomatic hepatic metastases
- •10) Known brain metastases, symptomatic or asymptomatic
- •11) History of clinically significant liver disease, current alcohol abuse or known active infection
- •12) History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- •13) Prior allogeneic stem cell or solid organ transplantation
- •14) History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computerised tomography (CT) scan
- •15) Active tuberculosis
- •16) Receipt of a live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 of 1st Treatment or anticipation that a live, attenuated vaccine will be required during atezolizumab treatment or within 5 months after the last dose of atezolizumab
- •17) Treatment with systemic immunostimulatory agents (including but not limited to interferons or interlukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to Cycle 1 Day 1 of 1st Treatment
- •18) Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, mycophenolate, and anti-tumour necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1 Day 1 of 1st Treatment, or anticipated requirement for systemic immunosuppressive medications during the trial
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study to evaluate talazoparib (BMN 673) in Patients with Germline BRCA Mutations with Locally Advanced and/or Metastatic Breast Cancerocally advanced and/or metastatic breast cancer with germline BRCA1 or BRCA2 mutationsMedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864EUCTR2013-003076-12-GBMedivation, Inc.84
招募中
2 期
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo StudyPremenopausal HR+/HER2- Metastatic Breast CancerNCT04819243Samsung Medical Center178
尚未招募
不适用
A randomized phase II clinical trial of talazoparib maintenance therapy in triple-negative breast cancer patients who showed platinum-sensitivity on first- or second-line platinum-based chemotherapyKCT0005671Yonsei University Health System, Severance Hospital206
进行中（未招募）
2 期
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerRecurrent Extensive Stage Small Cell Lung CarcinomaRefractory Extensive Stage Small Cell Lung CarcinomaNCT03672773Jonsson Comprehensive Cancer Center35
已完成
2 期
Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.gastric or gastro-esophageal junction adenocarcinomaJPRN-UMIN000009297West Japan Oncology Group90